Physician profile
Arif Husain
NPI 1043276918
$907.10
in general payments reported to CMS, 2019-2025
12 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.73 · 2020: $45.22 · 2021: $139 · 2022: $64.91 · 2023: $53.05 · 2024: $160 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.76 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $136.02 | 2020-2025 | |
| Axsome Therapeutics, INC. | $123.41 | 2024 | Auvelity |
| Alkermes, INC. | $120.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $101.68 | 2023-2025 | Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $67.98 | 2019-2020 | |
| Indivior INC. | $52.35 | 2022-2023 | Perseris |
| Otsuka America Pharmaceutical, INC. | $50.87 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Amneal Pharmaceuticals LLC | $49.08 | 2024-2025 | Crexont, Ongentys |
| Genentech USA, INC. | $29.79 | 2022 | |
| Acorda Therapeutics, INC | $20.45 | 2022 | |
| Livanova USA, INC. | $14.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.